Search company, investor...
Exscientia company logo

Exscientia

exscientia.ai

Founded Year

2012

Stage

IPO | IPO

Total Raised

$673.7M

Date of IPO

10/1/2021

Revenue

$0000 

About Exscientia

Exscientia (NASDAQ: EXAI) is an AI-driven, drug discovery, and design enterprise. Exscientia aims to use AI to discover and design better quality drugs with greater efficiency.

Headquarters Location

The Schrodinger Building Oxford Science Park

Oxford, England, OX4 4GE,

United Kingdom

+44 (0) 1865 818941

Missing: Exscientia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Exscientia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Exscientia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Exscientia is included in 5 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

B

Biopharma Tech

838 items

D

Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Exscientia Patents

Exscientia has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/4/2019

Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines

Application

Application Date

6/4/2019

Grant Date

Title

Related Topics

Adenosine receptor antagonists, Carbamates, Xanthines, Acetylcholinesterase inhibitors, Purines

Status

Application

Latest Exscientia News

6 ways health systems are using AI to improve patient care

Nov 21, 2022

Naomi Diaz - Monday, November 21st, 2022 Hospitals are using AI to improve health outcomes, produce predictive clinical insights and improve patient care. Here are six artificial intelligence projects health systems have recently created and deployed, as reported by Becker's Hospital Review: Rochester, Minn.-based Mayo Clinic is rolling out a tool designed to fight bias in AI models. The tool produces reports on how an AI model performs when it is tested on a dataset with different constraints, such as socioeconomic factors or race. Somerville, Mass.-based Mass General Brigham is among the first health systems to use a new artificial intelligence-powered medical imaging platform from Nuance Communications and Nvidia. The health system has used the platform to launch a breast density AI model that has reduced the waiting period for scan results from a period of days to minutes. Houston-based University of Texas MD Anderson Cancer Center is collaborating with artificial intelligence company Exscientia to develop new oncology treatments. The research collaboration will leverage Exscientia's precision medicine platform to identify novel anti-cancer small molecule compounds. Promising candidates will be developed and potentially advanced into clinical trials at MD Anderson. Researchers at Rochester, Minn.-based Mayo Clinic were able to successfully use artificial intelligence and Apple Watch ECG recordings to identify patients who had a weak heart pump. The AI algorithm, which used single-lead ECG data, was as accurate or slightly more accurate than a medical treadmill diagnostic test at detecting a weak heart pump. New Hyde Park, N.Y.-based Northwell Health 's research arm, Feinstein Institutes for Medical Research, built an artificial intelligence tool to help inform front-line staff on a patient's prognosis and severity of COVID-19. The researchers found that the AI-based model was accurate throughout the research period, even during surges and changing variants, and performs equally regardless of race, ethnicity or gender. Some Texas hospitals that are part of Nashville, Tenn.-based HCA Healthcare are using artificial intelligence-powered imaging technology. The new technology aims to transform cancer surgery with ultra-high-resolution, real-time technology.

Exscientia Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Exscientia Rank

Exscientia Frequently Asked Questions (FAQ)

  • When was Exscientia founded?

    Exscientia was founded in 2012.

  • Where is Exscientia's headquarters?

    Exscientia's headquarters is located at The Schrodinger Building, Oxford.

  • What is Exscientia's latest funding round?

    Exscientia's latest funding round is IPO.

  • How much did Exscientia raise?

    Exscientia raised a total of $673.7M.

  • Who are the investors of Exscientia?

    Investors of Exscientia include Bill & Melinda Gates Foundation, Novo Holdings, Bristol-Myers Squibb, GT Healthcare Capital Partners, SoftBank Group and 15 more.

  • Who are Exscientia's competitors?

    Competitors of Exscientia include Insilico Medicine, Cyclica, nference, Recursion, Causaly, Enveda Biosciences, METiS Therapeutics, Brightseed, BenevolentAI, Celsius Therapeutics and 32 more.

Compare Exscientia to Competitors

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

insitro Logo
insitro

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of Generative Adversarial Networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions for research and development. It was founded in 2014 and is based in Hong Kong.

Cyclica Logo
Cyclica

Cyclica offers artificial intelligence (AI) and computational biophysics based drug discovery process. Its structure-based and artificial intelligence (AI) augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. The company was founded in 2013 and is based in Toronto, Canada.

Healx Logo
Healx

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

Standigm Logo
Standigm

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.